A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: (RELEASE NCT04578210)

Background: Adoptive cell immunotherapies for opportunistic virus in immunocompromised patients using haploidentical memory T cells have shown to be safe and effective. Since severe cases of COVID-19 present a dysregulated immune system with T cell lymphopenia and a hyper-inflammatory state we have...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Martínez, Antonio, Martín-Quirós, Alejandro, Ferreras, Cristina, Al-Akioui, Karima, Mora-Rillo, Marta, Goterris, Rosa, Briones, María Luisa, Gasior, Mercedes, Amat, Paula, de Paz, Raquel, Guerra-García, Pilar, Queiruga-Parada, Javier, Bou, Merche, Mestre-Durán, Carmen, Borobia, Alberto, Carcas, Antonio J, Vicario, Jose Luis, Moreno, Miguel Ángel, Planelles, Dolores, Balas, Antonio, Eguizábal, Cristina, Soria, Bernat, Solano, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
704.Cellular Immunotherapies: Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701833/
http://dx.doi.org/10.1182/blood-2021-150847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701833/
http://dx.doi.org/10.1182/blood-2021-150847

Ejemplares similares